News

The companies believe sc28AT, a CD28 antagonist in preclinical development, may block graft rejection as well as the initiation and development of autoimmune diseases, while keeping the body's

The first agreement relates to the use of Crucell's PER.C6 technology in the production of adenoviral vectors expressing ceNOS (constituted endothelial nitric oxide synthase) for the treatment of

Ramelteon has a unique mechanism of action that selectively targets two receptors located in the brain's suprachiasmatic nucleus (SCN). The SCN is known as the body's 'master clock'

The trial was designed to determine how immunomodulating agents such as CRx-102 would affect various systemic inflammatory markers in individuals with periodontitis. In the primary endpoint of reduction

The trials have two phases. The first phase will be a dose escalation to evaluate safety and immune responses. Initially, low doses of the two vaccine components will

“We are pleased to have licensed this technology platform from Kalium as it enables Urigen to develop important and innovative treatments for the urology medical community,” said William

TNX-650 targets interleukin 13 (IL-13), an important growth factor for malignant Hodgkin's lymphoma cells. In preclinical testing, TNX-650 inhibited the function of IL-13 and blocked the proliferation of

Amphotericin B inhalation powder represents the first inhaled anti-fungal therapy under development for immunosuppressed patients. The fast track designation includes patients receiving organ or stem cell transplants, or

Dyax’ proprietary drug discovery technology is used to identify antibody, small protein and peptide compounds for clinical development. For example, Dyax identified its lead product candidate DX-88, and